Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Brought to you by

BI in cancer antibody discovery deal with Oxford BioTherapeutics

13 Apr 2022

Executive Summary

UK oncology drug and companion diagnostic developer Oxford BioTherapeutics Ltd. (OBT) has licensed Boehringer Ingelheim GMBH exclusive rights to develop and market its cancer antibodies.

Deal Industry
  • Pharmaceuticals
  • Biotechnology
    • Immuno-Oncology
    • Large Molecule
      • Antibodies
    • Drug Discovery Tools
      • Bioinformatics
      • Genomics-Proteomics
      • Molecular Diversity
Deal Status
  • Final
Deal Type
  • Alliance
    • Includes Royalty or Profit Split Information
    • R&D and Marketing (Licensing)

Related Companies

UsernamePublicRestriction

Register

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By